1887

Science and Money: Problems and Solutions

    Author: David B. Resnik1
    VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709
    AUTHOR AND ARTICLE INFORMATION AUTHOR AND ARTICLE INFORMATION
    • Published 15 December 2014
    • Corresponding author. Mailing address: National Institute of Environmental Health Sciences, National Institutes of Health, 111 Alexander Drive, Box 12233, Mail Drop CU 03, Research Triangle Park, NC 27709. Phone: 919-541-5658. Fax: 919-541-9854. E-mail: resnikd@niehs.nih.gov.
    • ©2014 Author(s). Published by the American Society for Microbiology.
    Source: J. Microbiol. Biol. Educ. December 2014 vol. 15 no. 2 159-161. doi:10.1128/jmbe.v15i2.792
MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • HTML
    24.72 Kb
  • PDF
    148.68 Kb
  • XML

    Abstract:

    Because science is a business replete with many different types of financial interests, eliminating or even drastically reducing them is not a realistic option. The best approach to dealing with financial interests in research is to implement policies designed to minimize or mitigate their impact on scientific integrity.

Key Concept Ranking

Clinical Trials
0.54534006
Clinical Research
0.46882248
Gene therapy
0.46701357
Cancer Treatment
0.4441375
Calcium
0.4375
0.54534006

References & Citations

1. Battelle. 2013 2014 Global R&D funding forecast. R&DMagazine. [Online.] http://www.battelle.org/docs/tpp/2014_global_rd_funding_forecast.pdf?sfvrsn=4
2. Bekelman JE, Li Y, Gross CP 2003 Scope and impact of financial conflicts of interest in biomedical research: a systematic review JAMA 289 454 465 10.1001/jama.289.4.454 12533125 http://dx.doi.org/10.1001/jama.289.4.454
3. Elliott KC 2011 Is a little pollution good for you? Oxford University Press New York NY 10.1093/acprof:oso/9780199755622.001.0001 http://dx.doi.org/10.1093/acprof:oso/9780199755622.001.0001
4. Friedberg M, Saffran B, Stinson T, Nelson W, Bennett C 1999 Evaluation of conflict of interest in new drugs use in oncology JAMA 282 1453 1457 10.1001/jama.282.15.1453 10535436 http://dx.doi.org/10.1001/jama.282.15.1453
5. Krimsky S 2003 Science in the private interest Rowman and Littlefield Lanham, MD
6. Lexchin J, Bero LA, Djulbegovic B, Clark O 2003 Pharmaceutical industry sponsorship and research outcome and quality: systematic review BMJ 326 1167 1170 10.1136/bmj.326.7400.1167 12775614 156458 http://dx.doi.org/10.1136/bmj.326.7400.1167
7. McGarity TO, Wagner WE 2012 Bending science Harvard University Press Cambridge, MA
8. Michaels D 2008 Doubt is their product Oxford University Press New York NY
9. Resnik DB 2007 The price of truth: how money affects the norms of science Oxford University Press New York NY 10.1093/acprof:oso/9780195309782.001.0001 http://dx.doi.org/10.1093/acprof:oso/9780195309782.001.0001
10. Resnik DB, Elliott KC 2013 Taking financial relationships into account when assessing research Account Res 20 184 205 10.1080/08989621.2013.788383 23672544 3954632 http://dx.doi.org/10.1080/08989621.2013.788383
11. Ridker PM, Torres J 2006 Reported outcomes in major cardiovascular clinical trials funded by for-profit and notfor-profit organizations: 2000–2005 JAMA 295 2270 2274 10.1001/jama.295.19.2270 16705108 http://dx.doi.org/10.1001/jama.295.19.2270
12. Shamoo AE, Resnik DB 2014 Responsible conduct of research 3rd ed Oxford University Press New York NY
13. Sismondo S 2008 Pharmaceutical company funding and its consequences: a qualitative systematic review Contemp Clin Trials 29 109 113 10.1016/j.cct.2007.08.001 http://dx.doi.org/10.1016/j.cct.2007.08.001
14. Stelfox H, Chua G, O’Rourke K, Detsky A 1998 Conflict of interest in the debate over calcium channel antagonists N Engl J Med 338 101 106 10.1056/NEJM199801083380206 9420342 http://dx.doi.org/10.1056/NEJM199801083380206
jmbe.v15i2.792.citations
jmbe/15/2
content/journal/jmbe/10.1128/jmbe.v15i2.792
Loading

Citations loading...

Supplemental Material

No supplementary material available for this content.

Loading

Article metrics loading...

/content/journal/jmbe/10.1128/jmbe.v15i2.792
2014-12-15
2017-11-24

Abstract:

Because science is a business replete with many different types of financial interests, eliminating or even drastically reducing them is not a realistic option. The best approach to dealing with financial interests in research is to implement policies designed to minimize or mitigate their impact on scientific integrity.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

/deliver/fulltext/jmbe/15/2/jmbe-15-159.xml.a.html?itemId=/content/journal/jmbe/10.1128/jmbe.v15i2.792&mimeType=html&fmt=ahah

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error